We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Stefano
Fedele
s.fedele@ucl.ac.uk
Sara
Fessehaye
sara.fessehaye@nhs.net
Rachel
Knight
rachel.knight@ucl.ac.uk
Prof
Stefano
Fedele
s.fedele@ucl.ac.uk
Diseases of oral cavity, salivary glands and jawsComplications of surgical and medical care, not elsewhere classifiedMalignant neoplasms of lip, oral cavity and pharynx
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Dry mouth is one of the most common complications of cancer radiotherapy to the head and neck. It is also known as
radiotherapy-induced xerostomia (RIX). RIX is debilitating condition as it is irreversible and can interfere with important
oral functions, such as chewing, swallowing, and speaking. It can also incrase the risk of dental and oral infections.
Overall it can reduce the quality of life (QoL) of affected individuals.
Doctors cannot assess easily the severity of RIX, as dry mouth is a symptom perceived by patients. It is however
possible to use dedicated questionnaires that ask questions about the intensity and consequences of having a dry
mouth. A number of questionnaires have been used in the past to assess RIX. It is however unclear whether they were
developed rigorously.
We have previously conducted a systematic review of the literature on this topic and concluded that the vast majority of
questionnaires used in the past were not tested accurately.
Therefore, the present study aims at re-testing rigorously these questionnaires in order to identify the questionnaires
that are most appropriate to use in clinical practice, so to assess the intensity of RIX.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of outcome measures;
You can take part if:
You may not be able to take part if:
• Under 18 years old. • Unable to give consent. • Unable to read, speak and write in English. • Developed xerostomia due to other disease (e.g. Sjogrens’s syndrome. GvHD, etc). • Having recurrent or metastatic cancer
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Stefano
Fedele
s.fedele@ucl.ac.uk
Rachel
Knight
rachel.knight@ucl.ac.uk
Prof
Stefano
Fedele
s.fedele@ucl.ac.uk
Sara
Fessehaye
sara.fessehaye@nhs.net
The study is sponsored by University College London and funded by NIHR Central Commissioning Facility (CCF); Ministry of Education (Saudi Arabia); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 37169
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
